BioCardia, Inc.

BCDA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-8.2M $-7.9M $-11.6M $-11.9M $-12.6M $-15.0M $-14.7M $-14.0M
Depreciation & Amortization $24.0K $67.0K $84.0K $82.0K $60.0K $68.0K $111.0K $88.0K
Depreciation $24.0K $67.0K $84.0K $82.0K $60.0K $68.0K $111.0K $88.0K
Amortization
Stock-Based Compensation $430.0K $741.0K $1.0M $1.2M $1.7M $3.0M $2.7M $2.8M
Net Cash from Operating Activities $-7.4M $-7.9M $-10.0M $-10.6M $-10.4M $-12.4M $-9.4M $-11.1M
Investing Activities
Capital Expenditures $7.0K $6.0K $12.0K $70.0K $116.0K $32.0K $146.0K $66.0K
Business Acquisitions
Net Cash from Investing Activities $-7.0K $-6.0K $-12.0K $-70.0K $-116.0K $-32.0K $-146.0K $-66.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $7.6M $9.2M $3.7M $5.1M $1.9M $28.2M $9.8M $3.8M
Net Change in Cash $125.0K $1.3M $-6.3M $-5.5M $-8.5M $15.8M $227.0K
Free Cash Flow $-7.4M $-7.9M $-10.0M $-10.6M $-10.5M $-12.4M $-9.6M $-11.1M
← Newer Page 1 of 2 Older →